BioCryst pops as FDA approves Orladeyo for young children

BioCryst shares rose after the FDA approved Orladeyo oral pellet form for children aged 2-12 with hereditary angioedema. The decision follows interim trial data showing strong safety and effectiveness. BioCryst is also seeking approvals in Europe, Japan, Canada and other regions. Shares gained over 4% in early Friday trade.